FXYD domain containing ion transport regulator 6 (FXYD6)

FXYD domain containing ion transport regulator 6 (FXYD6) is a single-pass transmembrane protein belonging to the FXYD family, which modulates the activity of the Na,K-ATPase sodium/potassium pump[1][2][3][7]. FXYD6 is widely expressed in nervous tissue, heart, kidney, and various other organs, functioning as a regulator of ion homeostasis and influencing cellular properties such as membrane potential, cell junction integrity, and neural signaling[1][3][4]. It has been implicated in the biology and pathophysiology of several diseases, most notably in cancers such as glioma and hepatocellular carcinoma, where it can serve as a prognostic biomarker and potential therapeutic target[1][2]. Genetic associations link FXYD6 to neurological disorders (schizophrenia, Alzheimer’s disease) and rare electrolyte disorders[1][3]. Experimentally, targeted inhibition by antibody can reduce tumor growth in vivo, indicating potential for drug development in oncology[2]. However, its broad tissue distribution and key physiological roles raise caution regarding systemic targeting, particularly concerning neurological and cardiac safety.

Other names

phosphohippolin

Inhibition of FXYD6 can decrease Na,K-ATPase activity and downstream signaling such as Src-ERK, reducing cancer cell proliferation and migration[2] Modulation of ion homeostasis and cell signaling pathways in neurons and other excitable tissues[1][3]